CancerDrs Find care

Kidney Cancer clinical trials

205 actively recruiting kidney cancer trials in the United States. Renal cell carcinoma (RCC) and related kidney malignancies.

Data from ClinicalTrials.gov · last refreshed · Kidney Cancer stats on SEER

50
Phase 1
84
Phase 2
8
Phase 3
1
Phase 4
62
Other

Kidney Cancer by the numbers (U.S.)

80,980
Estimated new cases (2025)
14,510
Estimated deaths (2025)
78.6%
5-year relative survival
65
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse kidney cancer trials by state

Texas 85 California 68 New York 64 Florida 50 Massachusetts 41 Ohio 41 Pennsylvania 40 Maryland 37 Michigan 36 Tennessee 36 Missouri 33 Illinois 31 Minnesota 31 North Carolina 30 Colorado 29 New Jersey 29 Arizona 26 Washington 24 Georgia 23 Connecticut 22 Virginia 21 Kentucky 19 Oregon 19 Wisconsin 19 Nebraska 18 South Carolina 18 District of Columbia 17 Indiana 17 Iowa 16 Utah 16 Arkansas 15 Oklahoma 15 Alabama 13 Louisiana 12 North Dakota 11 Rhode Island 10 Maine 9 Nevada 9 New Mexico 9 Delaware 8 Idaho 8 Kansas 8 South Dakota 8 Mississippi 7 New Hampshire 7 Vermont 7 West Virginia 7 Montana 6 Hawaii 5 Alaska 4 Wyoming 2

Top trials by phase + site coverage

Phase 2, Phase 3 Recruiting NIH

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Locations:
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona

+ 483 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Locations:
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona

+ 406 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spr…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04510597
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Kingman Regional Medical Center — Kingman, Arizona

+ 384 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Locations:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas

+ 253 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carc…

Sponsor: Arcus Biosciences, Inc.
NCT ID: NCT07011719
Locations:
  • City of Hope - Phoenix Cancer Center — Goodyear, Arizona
  • Mayo Clinic - Phoenix — Phoenix, Arizona
  • City Of Hope National Medical Center — Duarte, California

+ 25 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Sponsor: Xynomic Pharmaceuticals, Inc.
NCT ID: NCT03592472
Locations:
  • University Of UA Cancer Center(UACC)/DH-SJHMC — Phoenix, Arizona
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
  • UCSF Helen Diller Family Comphrensive Cancer Center - Hemato — San Francisco, California

+ 11 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07405164
Locations:
  • START San Antonio ( Site 0104) — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

R.E.C.K vs Exparel in Robotic Nephrectomy

The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT07092566
Locations:
  • Levine Cancer — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Anchorage Associates in Radiation Medicine — Anchorage, Alaska
  • Anchorage Radiation Therapy Center — Anchorage, Alaska

+ 576 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…

Sponsor: NRG Oncology
NCT ID: NCT05327686
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
  • PCR Oncology — Arroyo Grande, California

+ 310 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…

Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • USA Health Strada Patient Care Center — Mobile, Alabama
  • Providence Alaska Medical Center — Anchorage, Alaska

+ 174 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other …

Sponsor: Pfizer
NCT ID: NCT07227415
Locations:
  • Highlands Oncology Group — Fayetteville, Arkansas
  • Highlands Oncology Group — Rogers, Arkansas
  • Highlands Oncology Group — Springdale, Arkansas

+ 41 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 205 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20